Amylyx Stock: Why the Full Pipeline Story Matters

Summary

The idiom “never judge a book by its cover” can cut both ways when it comes to clinical-stage biotechnology companies like Amylyx Pharmaceuticals NASDAQ: AMLX. The stock is up over 140% in the last 12 months as the company has made progress on its pipeline. Amylyx Pharmaceuticals TodayAMLXAmylyx Pharmaceuticals$13.58 -0.35 (-2.51%) As of 05/22/2026 04:00 PM Eastern52-Week Range$4.64▼$18.60Price Target$23.00 One of the drugs in the pipeline is Avexitide, a treatment for post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. In early May, Amylyx announced it had completed full enrollment in its Phase 3 trial, LUCIDITY. Topline results are expected in Q3 2026, which is pivotal for the short-term outlook for AMLX.Get Amylyx Pharmaceuticals alerts:Sign Up However, this is a story that’s playing out in three distinct chapters that will take years to fully develop. And, as is the case with even large-cap biotech companies, execution is always a risk. Investors saw that with another company, Regeneron Pharmaceuticals NASDAQ: REGN, on May 18, when it delivered Phase 3 results for its melanoma study of fianlimab + Libtayo that failed to meet its primary endpoint versus Keytruda, the industry standard from Merck & Co. NYSE: MRK. That said, positive news is positive news. Amylyx is committed to developing treatments for diseases with high unmet needs. Here’s a full read on the company’s progress as of late May, 2026. Chapter 1: A GLP-1 Contrarian PlayAmylyx is taking the opposite approach to the GLP-1 boom: instead of developing agonists for weight loss, the company is developing a GLP-1 antagonist. Avexitide is a first-in-class GLP-1 antagonist that could become the first-ever FDA-approved therapy for post-bariatric hypoglycemia (PBH). This is a metabolic condition that affects approximately 8% of patients in the United States who have undergone one of the two most common types of bariatric surgery. A key consideration for investors is that PBH has a small address...